These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38881370)

  • 1. Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program.
    Unverdorben M; Colonna P; Jin J; Köhler S; Santamaria A; Saxena M; Borrow A; Chen C; von Heymann C; Vanassche T
    Clin Appl Thromb Hemost; 2024; 30():10760296241260728. PubMed ID: 38881370
    [No Abstract]   [Full Text] [Related]  

  • 2. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study.
    Colonna P; von Heymann C; Santamaria A; Saxena M; Vanassche T; Wolpert D; Laeis P; Wilkins R; Chen C; Unverdorben M
    Clin Cardiol; 2020 Jul; 43(7):769-780. PubMed ID: 32406557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design.
    Colonna P; von Heymann C; Santamaria A; Matsushita Y; Unverdorben M
    Clin Cardiol; 2018 Sep; 41(9):1123-1129. PubMed ID: 30069910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Periprocedural edoxaban interruption is associated with low bleeding and thromboembolic risk: the Italian data of the EMIT-AF/VTE study].
    Fazio G; Squizzato A; Mazzetti M; Mannarini A; Fischetti A; Colonna P
    G Ital Cardiol (Rome); 2021 Jan; 22(1):70-79. PubMed ID: 33470246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M; Middeldorp S; Coppens M
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
    Kubli KA; Snead JA; Cheng-Lai A
    Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].
    Weiss TW; Rohla M; Dieplinger B; Domanovits H; Fries D; Vosko MR; Gary T; Ay C
    Wien Med Wochenschr; 2018 Apr; 168(5-6):133-143. PubMed ID: 28236004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
    De Caterina R; Agnelli G; Laeis P; Unverdorben M; Rauer H; Wang CC; Nakamura M; Chiu KM; Reimitz PE; Koretsune Y; Chen C; Thee U; Kaburagi J; Kim YH; Choi WI; Yamashita T; Cohen A; Kirchhof P
    Clin Cardiol; 2019 Dec; 42(12):1147-1154. PubMed ID: 31650560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
    Barrios V; Escobar C
    Future Cardiol; 2016 Jul; 12(4):419-33. PubMed ID: 27121025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
    Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
    Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
    Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
    N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.
    Chao TF; Chen SA; Ruff CT; Hamershock RA; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1518-1527. PubMed ID: 30590425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
    Gibson CM; Finks SW
    Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban, a Novel Oral Factor Xa Inhibitor.
    Minor C; Tellor KB; Armbruster AL
    Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
    Van Mieghem NM; Unverdorben M; Valgimigli M; Mehran R; Boersma E; Baber U; Hengstenberg C; Shi M; Chen C; Saito S; Veltkamp R; Vranckx P; Dangas GD
    Am Heart J; 2018 Nov; 205():63-69. PubMed ID: 30172099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.
    Steffel J; Ruff CT; Hamershock RA; Murphy SA; Senior R; Roy D; Lanz HJ; Mercuri MF; Antman EM; Giugliano RP
    Int J Cardiol; 2017 Oct; 244():192-195. PubMed ID: 28625512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
    Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MP; Cohen AT; Meyer G; Grosso MA; Raskob G; Weitz JI; Zhang G; Buller H
    Thromb Haemost; 2016 Sep; 116(4):747-53. PubMed ID: 27440518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Zelniker TA; Ardissino M; Andreotti F; O'Donoghue ML; Yin O; Park JG; Murphy SA; Ruff CT; Lanz HJ; Antman EM; Braunwald E; Giugliano RP; Merlini PA
    Circulation; 2021 Feb; 143(7):673-684. PubMed ID: 33587659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Hurst KV; O'Callaghan JM; Handa A
    Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.